OpGen Co-Markets COVID-19 Antibody Test Kit
10 August 2020 - 6:15AM
As disclosed in OpGen, Inc.’s (NASDAQ: OPGN) (“OpGen” or “the
Company”) July 13, 2020 press release, we have commenced marketing
and promotion, on a non-exclusive basis, of certain products
offered by Menarini Silicon Biosystems (MSB) to infectious disease
healthcare providers and researchers. As part of the
co-promotion relationship, OpGen is marketing and promoting the
CELLSEARCH system, CELLSEARCH CEC kit, and certain COVID-19 related
products that are sold and distributed by MSB on a non-exclusive
basis. OpGen is authorized to market and promote such
products in the United States, Canada, and Mexico under a strategic
co-promotion agreement entered into by OpGen and MSB. As
described in our tweet on August 7, 2020, the COVID-19 related
products include an IgG/IgM Rapid Test Cassette that is
manufactured by Healgen and sold by MSB, which is an antibody test
that provides results in as fast as 10 minutes. As further
described at http://www.siliconbiosystems.com/covid-19-tests, the
IgG/IgM Rapid Test Cassette has been authorized by the FDA under an
emergency use authorization for use by authorized
laboratories. The test has been authorized only for the
presence of IgM and IgG antibodies against SARS-CoV-2, not for any
other viruses or pathogens. Under the terms of the
co-promotion agreement, OpGen is entitled to certain payments based
on MSB’s net sales from customers referred by OpGen for such
products, including the IgG/IgM Rapid Test Cassette. The
parties expect to continue to expand the portfolio of COVID-19
products available as part of the non-exclusive co-promotion
relationship.
About OpGen, Inc.
OpGen, Inc. (Gaithersburg, MD, USA) is a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease.
Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we
are developing and commercializing molecular microbiology solutions
helping to guide clinicians with more rapid and actionable
information about life threatening infections to improve patient
outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s product
portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas
Lighthouse, and the ARES Technology Platform including ARESdb,
using NGS technology and AI-powered bioinformatics solutions for
antibiotic response prediction.
OpGen Forward-Looking
Statement
This press release includes statements regarding
the Menarini Silicon Biosystems commercial partnership for COVID-19
related tests by OpGen. These statements and other statements
regarding the Companies’ future plans and goals constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 and are intended to qualify for the safe
harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that are often difficult to predict, are beyond
our control, and which may cause results to differ materially from
expectations. Factors that could cause our results to differ
materially from those described include, but are not limited to,
our ability to successfully, timely and cost-effectively develop,
seek and obtain regulatory clearance for and commercialize our
product and services offerings, the rate of adoption of our
products and services by hospitals and other healthcare providers,
the realization of expected benefits of our business combination
transaction with Curetis GmbH, the success of our commercialization
efforts, the impact of COVID-19 on the Company’s operations,
financial results, and commercialization efforts as well as on
capital markets and general economic conditions, the effect on our
business of existing and new regulatory requirements, and other
economic and competitive factors. For a discussion of the most
significant risks and uncertainties associated with OpGen's
business, please review the Company’s filings with the Securities
and Exchange Commission. You are cautioned not to place undue
reliance on these forward-looking statements, which are based on
our expectations as of the date of this press release and speak
only as of the date of this press release. We undertake no
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information, please visit www.opgen.com.
OpGen:Oliver SchachtPresident and
CEOInvestorRelations@opgen.com
OpGen Press Contact:Matthew Bretzius FischTank
Marketing and PRmatt@fischtankpr.com
OpGen Investor Contact:Megan Paul Edison Group
mpaul@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Sep 2024 to Oct 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Oct 2023 to Oct 2024